Market news
-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient also achieved 84.6% reduction in target lesion size, as previously reported by Genelux, exceeding the reduction achieved following first-line therapy -- -- Findings support the potential of systemically administered Olvi-Vec to drive anti-tumor activity and enhance responsiveness t
Tipranks Press Release.
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates anticipated in 2026 -- -- Recently published Phase 1b/2 VIRO-15 translational analyses of heavily-pre-treated ovarian cancer patients support Olvi-Vec’s potential to overcome resistance biology and synergize with platinum chemotherapy -- -- $18.7 million in cash, cash equivalents, m
This is the newest page. Registered accounts read further back.